Use of CD25 antibodies in immunotherapy

Details for Australian Patent Application No. 2006233718 (hide)

Owner Novartis AG

Inventors Katopodis, Andreas

Agent Davies Collison Cave

Pub. Number AU-A-2006233718

PCT Pub. Number WO2006/108670

Priority 0507696.3 15.04.05 GB

Filing date 13 April 2006

Wipo publication date 19 October 2006

International Classifications

A61K 31/00 (2006.01)

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

Event Publications

25 October 2007 PCT application entered the National Phase

  PCT publication WO2006/108670 Priority application(s): WO2006/108670

20 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006233719-3,4-Dihydro-benzo[e][1,3]oxazin-2-ones

2006233715-Method of treatment using GH antagonist and somatostatin agonist